Mon, Oct 20, 2014, 11:55 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

  • btimnextmicrosoft btimnextmicrosoft Jun 17, 2013 12:23 AM Flag

    Here is some info from a company PDF

    Licensing Partners: Territories
    IntelliCell has licensed its Technology to International partners for large
    upfront payments and ongoing royalties.
    􀂃 Licensed by RegenaStem in Canada (operating as IntelliCell
    BioSciences of Canada) for $500,000 upfront and a 30% share of
    􀂃 Licensed by Cell-Innovations, Pty Limited in Australia for $700,000
    upfront and a 12.5% share of revenues.
    􀂃 Middle East led by Saudi Arabia
    􀂃 Thailand
    􀂃 Malaysia
    􀂃 Indonesia
    Technology Licensing Cont.
    􀂃 $150,000 in upfront licensing fees for
    equipment, installation, and training.
    􀂃 Yields high margin revenues for IntelliCell.
    􀂃 $1,000 in per procedure fees to IntelliCell.
    􀂃 Two procedures per week per lab
    generates $100,000 in annual revenues
    for IntelliCell.
    􀂃 IntelliCell estimates 100 labs will be
    operational by year-end 2013.
    Superior Technology
    Using IntelliCell’s Proprietary Ultrasound Cavitation Technique, SVFs can
    be separated at low cost and in less time, as compared to competing
    technologies that utilize enzymes.
    An antibody flow cytometry study performed by Millipore, a division of
    Merck, confirms the high-quality composition of IntelliCell SVFs.

0.00030.0000(0.00%)Oct 20 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.